Author

R. Falach

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 4 Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

M. Aftalion· 4 shared D. Gur· 3 shared E. Makdasi· 3 shared O. Mazor· 3 shared R. Alcalay· 3 shared R. Rosenfeld· 3 shared S. Lazar· 3 shared T. Chitlaru· 3 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Aftalion

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CRISPR screens for host factors critical for infection by SARS-CoV-2 variants of concern identify GATA6 as a central modulator of ACE2.

M. Israeli, Y. Finkel, Y. Yahalom-Rone, N. Paran, T. Chitlaru, O. Israeli, I. Cohen-Gihon, M. Aftalion, R. Falach, U. Elia, I. Nemet, L. Kliker, M. Mandelboim, A. Beth-Din, T. Israely, , A. Bercovich-Kinori

This study uses CRISPR screens to identify host factors critical for SARS-CoV-2 infection, finding GATA6 as a key modulator of ACE2 expression and viral entry.

bioRxiv · Jul 19, 2021 · PreprintMicrobiology

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice

T. Noy-Porat, A. Mechaly, Y. Levy, E. Makdasi, R. Alcalay, D. Gur, M. Aftalion, R. Falach, S. Leviatan Ben-Arye, S. Lazar, A. Zauberman, E. Epstein, T. Chitlaru, S. Weiss, H. Achdout, , R. Rosenfeld

This study identifies and characterizes neutralizing antibodies targeting the SARS-CoV-2 spike N-terminal domain, showing their protective efficacy in mice.

bioRxiv · Feb 2, 2021Immunology

Mice with Induced Pulmonary Comorbidities Display Severe Lung Inflammation and Mortality following Exposure to SARS-CoV-2

R. Falach, L. Bar-On, S. Lazar, T. Kadar, O. Mazor, M. Aftalion, D. Gur, O. Shifman, O. Israeli, I. Cohen-Gihon, G. Zaide, H. Gutman, Y. Evgy, Y. Vagima, E. Makdasi, , T. Sabo

This study shows that CD-1 mice with induced pulmonary comorbidities develop severe lung inflammation and high mortality after SARS-CoV-2 infection.

bioRxiv · Oct 28, 2020 · PreprintPathology

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

R. Rosenfeld, T. Noy-Porat, A. Mechaly, E. Makdasi, Y. Levy, R. Alcalay, R. Falach, M. Aftalion, E. Epstein, D. Gur, T. Chitlaru, E. B. Vitner, S. Melamed, B. Politi, A. Zauberman, , O. Mazor

This study shows that the human monoclonal antibody MD65 can rescue 100% of SARS-CoV-2 infected mice when administered up to 3 days post-exposure.

bioRxiv · Oct 26, 2020Immunology